{"id":833359,"date":"2025-04-03T06:03:55","date_gmt":"2025-04-03T10:03:55","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/beigene-provides-update-on-the-ociperlimab-bgb-a1217-clinical-development-program\/"},"modified":"2025-04-03T06:03:55","modified_gmt":"2025-04-03T10:03:55","slug":"beigene-provides-update-on-the-ociperlimab-bgb-a1217-clinical-development-program","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/beigene-provides-update-on-the-ociperlimab-bgb-a1217-clinical-development-program\/","title":{"rendered":"BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program"},"content":{"rendered":"

<\/p>\n

BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program<\/b><\/p>\n

SAN CARLOS, Calif.–(BUSINESS WIRE<\/a>)–
\nBeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the discontinuation of its clinical development program for ociperlimab (BGB-A1217), an anti-TIGIT antibody, as a potential treatment for lung cancer.\n<\/p>\n

\nThe Independent Data Monitoring Committee recommended terminating the ongoing Phase 3 AdvanTIG-302 trial (NCT04746924<\/a>) based on its findings as part of a pre-planned futility analysis. The overall efficacy and safety data assessment suggested that the study was unlikely to meet the primary endpoint of overall survival. No new safety signals were observed. After thorough deliberation, the Company has made the decision to terminate the trial.\n<\/p>\n

\n\u201cWe evaluate our clinical programs to focus our resources on the most promising clinically differentiated candidates while thoughtfully de-prioritizing others. Our commitment remains steadfast: to discover and develop innovative treatments that are more affordable and accessible to cancer patients worldwide,\u201d said Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeiGene. \u201cWe thank the investigators, their patients, and support staff whose participation and dedication made this research possible.\u201d\n<\/p>\n

\nResults from this study will be shared at a later date to help advance science and the understanding of anti-TIGIT activity.\n<\/p>\n

About BeiGene<\/b><\/p>\n

\nBeiGene, which plans to change its name to BeOne Medicines Ltd., is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of more than 11,000 colleagues spans six continents. To learn more about BeiGene, please visit www.beigene.com<\/a>.\n<\/p>\n

Forward-Looking Statements<\/b><\/p>\n

\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the ability of results from the AdvanTIG-302 trial to help advance science and the understanding of anti-TIGIT activity; and BeiGene\u2019s plans, commitments, aspirations, and goals under the heading \u201cAbout BeiGene.\u201d Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene\u2019s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing, and progress of clinical trials and marketing approval; BeiGene\u2019s ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeiGene\u2019s ability to obtain and maintain protection of intellectual property for its medicines and technology; BeiGene\u2019s reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeiGene\u2019s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products;BeiGene\u2019s ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled \u201cRisk Factors\u201d in BeiGene\u2019s most recent annual report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene\u2019s subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law.\n<\/p>\n

\nTo access BeiGene media resources, please visit ourNews & Media<\/b><\/a>site.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20250403796676\/en\/<\/a><\/span><\/p>\n

Investor Contact
\n<\/b>
Liza Heapes
\n
+1 857-302-5663
\n
ir@beigene.com<\/a><\/p>\n

Media Contact
\n<\/b>
Kyle Blankenship
\n
+1 667-351-5176
\n
media@beigene.com<\/a><\/p>\n

KEYWORDS:<\/b> United States North America California<\/p>\n

INDUSTRY KEYWORDS:<\/b> Oncology Health Clinical Trials Research Science Pharmaceutical Biotechnology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program SAN CARLOS, Calif.–(BUSINESS WIRE)– BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the discontinuation of its clinical development program for ociperlimab (BGB-A1217), an anti-TIGIT antibody, as a potential treatment for lung cancer. The Independent Data Monitoring Committee recommended terminating the ongoing Phase 3 AdvanTIG-302 trial (NCT04746924) based on its findings as part of a pre-planned futility analysis. The overall efficacy and safety data assessment suggested that the study was unlikely to meet the primary endpoint of overall survival. No new safety signals were observed. After thorough deliberation, the Company has made the decision to … <\/p>\n

Continue reading “BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-833359","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nBeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/beigene-provides-update-on-the-ociperlimab-bgb-a1217-clinical-development-program\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program SAN CARLOS, Calif.–(BUSINESS WIRE)– BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the discontinuation of its clinical development program for ociperlimab (BGB-A1217), an anti-TIGIT antibody, as a potential treatment for lung cancer. The Independent Data Monitoring Committee recommended terminating the ongoing Phase 3 AdvanTIG-302 trial (NCT04746924) based on its findings as part of a pre-planned futility analysis. The overall efficacy and safety data assessment suggested that the study was unlikely to meet the primary endpoint of overall survival. No new safety signals were observed. After thorough deliberation, the Company has made the decision to … Continue reading "BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/beigene-provides-update-on-the-ociperlimab-bgb-a1217-clinical-development-program\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-03T10:03:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250403796676r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/beigene-provides-update-on-the-ociperlimab-bgb-a1217-clinical-development-program\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/beigene-provides-update-on-the-ociperlimab-bgb-a1217-clinical-development-program\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program\",\"datePublished\":\"2025-04-03T10:03:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/beigene-provides-update-on-the-ociperlimab-bgb-a1217-clinical-development-program\\\/\"},\"wordCount\":661,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/beigene-provides-update-on-the-ociperlimab-bgb-a1217-clinical-development-program\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250403796676r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/beigene-provides-update-on-the-ociperlimab-bgb-a1217-clinical-development-program\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/beigene-provides-update-on-the-ociperlimab-bgb-a1217-clinical-development-program\\\/\",\"name\":\"BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/beigene-provides-update-on-the-ociperlimab-bgb-a1217-clinical-development-program\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/beigene-provides-update-on-the-ociperlimab-bgb-a1217-clinical-development-program\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250403796676r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2025-04-03T10:03:55+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/beigene-provides-update-on-the-ociperlimab-bgb-a1217-clinical-development-program\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/beigene-provides-update-on-the-ociperlimab-bgb-a1217-clinical-development-program\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/beigene-provides-update-on-the-ociperlimab-bgb-a1217-clinical-development-program\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250403796676r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250403796676r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/beigene-provides-update-on-the-ociperlimab-bgb-a1217-clinical-development-program\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/beigene-provides-update-on-the-ociperlimab-bgb-a1217-clinical-development-program\/","og_locale":"en_US","og_type":"article","og_title":"BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program - Market Newsdesk","og_description":"BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program SAN CARLOS, Calif.–(BUSINESS WIRE)– BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the discontinuation of its clinical development program for ociperlimab (BGB-A1217), an anti-TIGIT antibody, as a potential treatment for lung cancer. The Independent Data Monitoring Committee recommended terminating the ongoing Phase 3 AdvanTIG-302 trial (NCT04746924) based on its findings as part of a pre-planned futility analysis. The overall efficacy and safety data assessment suggested that the study was unlikely to meet the primary endpoint of overall survival. No new safety signals were observed. After thorough deliberation, the Company has made the decision to … Continue reading \"BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/beigene-provides-update-on-the-ociperlimab-bgb-a1217-clinical-development-program\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-03T10:03:55+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250403796676r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/beigene-provides-update-on-the-ociperlimab-bgb-a1217-clinical-development-program\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/beigene-provides-update-on-the-ociperlimab-bgb-a1217-clinical-development-program\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program","datePublished":"2025-04-03T10:03:55+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/beigene-provides-update-on-the-ociperlimab-bgb-a1217-clinical-development-program\/"},"wordCount":661,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/beigene-provides-update-on-the-ociperlimab-bgb-a1217-clinical-development-program\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250403796676r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/beigene-provides-update-on-the-ociperlimab-bgb-a1217-clinical-development-program\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/beigene-provides-update-on-the-ociperlimab-bgb-a1217-clinical-development-program\/","name":"BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/beigene-provides-update-on-the-ociperlimab-bgb-a1217-clinical-development-program\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/beigene-provides-update-on-the-ociperlimab-bgb-a1217-clinical-development-program\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250403796676r1&sid=flmnd&distro=nx&lang=en","datePublished":"2025-04-03T10:03:55+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/beigene-provides-update-on-the-ociperlimab-bgb-a1217-clinical-development-program\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/beigene-provides-update-on-the-ociperlimab-bgb-a1217-clinical-development-program\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/beigene-provides-update-on-the-ociperlimab-bgb-a1217-clinical-development-program\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250403796676r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250403796676r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/beigene-provides-update-on-the-ociperlimab-bgb-a1217-clinical-development-program\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/833359","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=833359"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/833359\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=833359"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=833359"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=833359"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}